Structured Review

Santa Cruz Biotechnology anti eno1
Anti Eno1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti eno1/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti eno1 - by Bioz Stars, 2024-07
86/100 stars

Images


Structured Review

Santa Cruz Biotechnology anti eno1
Anti Eno1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti eno1/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti eno1 - by Bioz Stars, 2024-07
86/100 stars

Images


Structured Review

Santa Cruz Biotechnology anti eno1 antibody
Forest plot illustrating the association of <t>ENO1</t> expression with AML patient overall survival. The hazard ratios (HR) of individual studies are shown as squares sized to reflect the indicated weight of each study in the overall estimate; 95% confidence intervals (CI) are shown as horizontal lines. The pooled HR from all studies combined (total, random effects) is shown as a diamond. The calculated p -value and heterogeneity estimate (I 2 ) are indicated.
Anti Eno1 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti eno1 antibody/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti eno1 antibody - by Bioz Stars, 2024-07
86/100 stars

Images

1) Product Images from "High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia"

Article Title: High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia

Journal: Cancers

doi: 10.3390/cancers16050884

Forest plot illustrating the association of ENO1 expression with AML patient overall survival. The hazard ratios (HR) of individual studies are shown as squares sized to reflect the indicated weight of each study in the overall estimate; 95% confidence intervals (CI) are shown as horizontal lines. The pooled HR from all studies combined (total, random effects) is shown as a diamond. The calculated p -value and heterogeneity estimate (I 2 ) are indicated.
Figure Legend Snippet: Forest plot illustrating the association of ENO1 expression with AML patient overall survival. The hazard ratios (HR) of individual studies are shown as squares sized to reflect the indicated weight of each study in the overall estimate; 95% confidence intervals (CI) are shown as horizontal lines. The pooled HR from all studies combined (total, random effects) is shown as a diamond. The calculated p -value and heterogeneity estimate (I 2 ) are indicated.

Techniques Used: Expressing

ENO1 protein expression in bone marrow trephine biopsies from AML at diagnosis and remission compared to MDS at diagnosis. Representative low power (20×) micrographs of immunohistochemical staining for ENO1 in ( A ) AML at diagnosis, ( B ) AML at remission, and ( C ) MDS at diagnosis, where presence of ENO1 is indicated by brown staining. QuPath analysis results for the percentage of positive cells ( D ) and H-score staining intensity ( E ) in each cohort. Comparison of blast cell percentages from bone marrow aspirates is illustrated in ( F ), and lack of correlation with ENO1 percentage of positive cell staining in ( G ) and H-score in ( H ). Bar graphs illustrate median/interquartile range. Ns = not significant.
Figure Legend Snippet: ENO1 protein expression in bone marrow trephine biopsies from AML at diagnosis and remission compared to MDS at diagnosis. Representative low power (20×) micrographs of immunohistochemical staining for ENO1 in ( A ) AML at diagnosis, ( B ) AML at remission, and ( C ) MDS at diagnosis, where presence of ENO1 is indicated by brown staining. QuPath analysis results for the percentage of positive cells ( D ) and H-score staining intensity ( E ) in each cohort. Comparison of blast cell percentages from bone marrow aspirates is illustrated in ( F ), and lack of correlation with ENO1 percentage of positive cell staining in ( G ) and H-score in ( H ). Bar graphs illustrate median/interquartile range. Ns = not significant.

Techniques Used: Expressing, Immunohistochemical staining, Staining, Comparison

 Anti-ENO1 antibody  levels in AML, MDS, and control cohorts.
Figure Legend Snippet: Anti-ENO1 antibody levels in AML, MDS, and control cohorts.

Techniques Used:

Anti-ENO1 antibodies in AML and MDS patients and controls. ( A ) Box plot showing median anti-ENO1 levels measured for each cohort, with whiskers and outliers calculated using Tukey’s method. ( B ) Scatterplot of age vs. anti-ENO1 levels showing linear trend lines.
Figure Legend Snippet: Anti-ENO1 antibodies in AML and MDS patients and controls. ( A ) Box plot showing median anti-ENO1 levels measured for each cohort, with whiskers and outliers calculated using Tukey’s method. ( B ) Scatterplot of age vs. anti-ENO1 levels showing linear trend lines.

Techniques Used:

Characteristics of the MDS patient cohort.
Figure Legend Snippet: Characteristics of the MDS patient cohort.

Techniques Used:

Characteristics of the AML patient cohort.
Figure Legend Snippet: Characteristics of the AML patient cohort.

Techniques Used: Mutagenesis

Anti-ENO1 antibodies in AML patients. ( A ) Scatterplot of BM blast percentage vs. anti-ENO1 levels showing linear trend line (solid red line) and 95% confident intervals (dotted red lines). ( B ) Comparison of Kaplan–Meier curves for AML patients with anti-ENO1 levels above and below the calculated median of 1.39 ng/mL.
Figure Legend Snippet: Anti-ENO1 antibodies in AML patients. ( A ) Scatterplot of BM blast percentage vs. anti-ENO1 levels showing linear trend line (solid red line) and 95% confident intervals (dotted red lines). ( B ) Comparison of Kaplan–Meier curves for AML patients with anti-ENO1 levels above and below the calculated median of 1.39 ng/mL.

Techniques Used: Comparison


Structured Review

Santa Cruz Biotechnology enolase 1
Glycolytic enzyme expression and protein levels did not change in HUVECs exposed to steady laminar versus oscillating disturbed flow. Relative ( A ) mRNA levels measured via RT-PCR, and ( B ) protein levels measured via Western blot of glycolytic enzymes in HUVEC exposed to static culture (S), steady laminar flow (L), or oscillating disturbed flow (D). GLUT1: glucose transporter 1, GLUT3: glucose transporter 3, HK1: hexokinase 1, HK2: hexokinase 2, GPI: glucose-6-phosphate isomerase, PFK-1: phosphofructokinase-1, PFKFB3: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, ALDO-A: aldolase A, ALDO-C: aldolase C, TPI-1: Triosephosphate isomerase-1, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, PGK-1: phosphoglycerate kinase-1, PGK-2: phosphoglycerate kinase-2, PGM-1: phosphoglucomutase-1, PGM-5: phosphoglucomutase-5, <t>ENO-1:</t> <t>enolase-1,</t> ENO-3: enolase-3, LDH-A: lactate dehydrogenase A, LDH-B: lactate dehydrogenase B, PKM-1: pyruvate kinase-1, PFKM-2: pyruvate kinase-2. n = 3 samples per condition.
Enolase 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/enolase 1/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
enolase 1 - by Bioz Stars, 2024-07
86/100 stars

Images

1) Product Images from "Steady Laminar Flow Decreases Endothelial Glycolytic Flux While Enhancing Proteoglycan Synthesis and Antioxidant Pathways"

Article Title: Steady Laminar Flow Decreases Endothelial Glycolytic Flux While Enhancing Proteoglycan Synthesis and Antioxidant Pathways

Journal: International Journal of Molecular Sciences

doi: 10.3390/ijms25052485

Glycolytic enzyme expression and protein levels did not change in HUVECs exposed to steady laminar versus oscillating disturbed flow. Relative ( A ) mRNA levels measured via RT-PCR, and ( B ) protein levels measured via Western blot of glycolytic enzymes in HUVEC exposed to static culture (S), steady laminar flow (L), or oscillating disturbed flow (D). GLUT1: glucose transporter 1, GLUT3: glucose transporter 3, HK1: hexokinase 1, HK2: hexokinase 2, GPI: glucose-6-phosphate isomerase, PFK-1: phosphofructokinase-1, PFKFB3: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, ALDO-A: aldolase A, ALDO-C: aldolase C, TPI-1: Triosephosphate isomerase-1, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, PGK-1: phosphoglycerate kinase-1, PGK-2: phosphoglycerate kinase-2, PGM-1: phosphoglucomutase-1, PGM-5: phosphoglucomutase-5, ENO-1: enolase-1, ENO-3: enolase-3, LDH-A: lactate dehydrogenase A, LDH-B: lactate dehydrogenase B, PKM-1: pyruvate kinase-1, PFKM-2: pyruvate kinase-2. n = 3 samples per condition.
Figure Legend Snippet: Glycolytic enzyme expression and protein levels did not change in HUVECs exposed to steady laminar versus oscillating disturbed flow. Relative ( A ) mRNA levels measured via RT-PCR, and ( B ) protein levels measured via Western blot of glycolytic enzymes in HUVEC exposed to static culture (S), steady laminar flow (L), or oscillating disturbed flow (D). GLUT1: glucose transporter 1, GLUT3: glucose transporter 3, HK1: hexokinase 1, HK2: hexokinase 2, GPI: glucose-6-phosphate isomerase, PFK-1: phosphofructokinase-1, PFKFB3: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, ALDO-A: aldolase A, ALDO-C: aldolase C, TPI-1: Triosephosphate isomerase-1, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, PGK-1: phosphoglycerate kinase-1, PGK-2: phosphoglycerate kinase-2, PGM-1: phosphoglucomutase-1, PGM-5: phosphoglucomutase-5, ENO-1: enolase-1, ENO-3: enolase-3, LDH-A: lactate dehydrogenase A, LDH-B: lactate dehydrogenase B, PKM-1: pyruvate kinase-1, PFKM-2: pyruvate kinase-2. n = 3 samples per condition.

Techniques Used: Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot

PCR primer sequences.
Figure Legend Snippet: PCR primer sequences.

Techniques Used: Sequencing


Structured Review

Santa Cruz Biotechnology eno1
Eno1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eno1/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
eno1 - by Bioz Stars, 2024-07
86/100 stars

Images


Structured Review

Santa Cruz Biotechnology anti eno1
Anti Eno1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti eno1/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti eno1 - by Bioz Stars, 2024-07
86/100 stars

Images


Structured Review

Santa Cruz Biotechnology antibodies eno1
Antibodies Eno1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies eno1/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
antibodies eno1 - by Bioz Stars, 2024-07
86/100 stars

Images


Structured Review

Santa Cruz Biotechnology α eno1
α Eno1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/α eno1/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
α eno1 - by Bioz Stars, 2024-07
86/100 stars

Images


Structured Review

Santa Cruz Biotechnology eno1
Eno1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eno1/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
eno1 - by Bioz Stars, 2024-07
86/100 stars

Images


Structured Review

Santa Cruz Biotechnology anti enolase 1
Anti Enolase 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti enolase 1/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti enolase 1 - by Bioz Stars, 2024-07
86/100 stars

Images

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Santa Cruz Biotechnology anti eno1
    Anti Eno1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti eno1/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti eno1 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Santa Cruz Biotechnology anti eno1 antibody
    Forest plot illustrating the association of <t>ENO1</t> expression with AML patient overall survival. The hazard ratios (HR) of individual studies are shown as squares sized to reflect the indicated weight of each study in the overall estimate; 95% confidence intervals (CI) are shown as horizontal lines. The pooled HR from all studies combined (total, random effects) is shown as a diamond. The calculated p -value and heterogeneity estimate (I 2 ) are indicated.
    Anti Eno1 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti eno1 antibody/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti eno1 antibody - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Santa Cruz Biotechnology enolase 1
    Glycolytic enzyme expression and protein levels did not change in HUVECs exposed to steady laminar versus oscillating disturbed flow. Relative ( A ) mRNA levels measured via RT-PCR, and ( B ) protein levels measured via Western blot of glycolytic enzymes in HUVEC exposed to static culture (S), steady laminar flow (L), or oscillating disturbed flow (D). GLUT1: glucose transporter 1, GLUT3: glucose transporter 3, HK1: hexokinase 1, HK2: hexokinase 2, GPI: glucose-6-phosphate isomerase, PFK-1: phosphofructokinase-1, PFKFB3: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, ALDO-A: aldolase A, ALDO-C: aldolase C, TPI-1: Triosephosphate isomerase-1, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, PGK-1: phosphoglycerate kinase-1, PGK-2: phosphoglycerate kinase-2, PGM-1: phosphoglucomutase-1, PGM-5: phosphoglucomutase-5, <t>ENO-1:</t> <t>enolase-1,</t> ENO-3: enolase-3, LDH-A: lactate dehydrogenase A, LDH-B: lactate dehydrogenase B, PKM-1: pyruvate kinase-1, PFKM-2: pyruvate kinase-2. n = 3 samples per condition.
    Enolase 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/enolase 1/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    enolase 1 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Santa Cruz Biotechnology eno1
    Glycolytic enzyme expression and protein levels did not change in HUVECs exposed to steady laminar versus oscillating disturbed flow. Relative ( A ) mRNA levels measured via RT-PCR, and ( B ) protein levels measured via Western blot of glycolytic enzymes in HUVEC exposed to static culture (S), steady laminar flow (L), or oscillating disturbed flow (D). GLUT1: glucose transporter 1, GLUT3: glucose transporter 3, HK1: hexokinase 1, HK2: hexokinase 2, GPI: glucose-6-phosphate isomerase, PFK-1: phosphofructokinase-1, PFKFB3: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, ALDO-A: aldolase A, ALDO-C: aldolase C, TPI-1: Triosephosphate isomerase-1, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, PGK-1: phosphoglycerate kinase-1, PGK-2: phosphoglycerate kinase-2, PGM-1: phosphoglucomutase-1, PGM-5: phosphoglucomutase-5, <t>ENO-1:</t> <t>enolase-1,</t> ENO-3: enolase-3, LDH-A: lactate dehydrogenase A, LDH-B: lactate dehydrogenase B, PKM-1: pyruvate kinase-1, PFKM-2: pyruvate kinase-2. n = 3 samples per condition.
    Eno1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/eno1/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    eno1 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Santa Cruz Biotechnology antibodies eno1
    Glycolytic enzyme expression and protein levels did not change in HUVECs exposed to steady laminar versus oscillating disturbed flow. Relative ( A ) mRNA levels measured via RT-PCR, and ( B ) protein levels measured via Western blot of glycolytic enzymes in HUVEC exposed to static culture (S), steady laminar flow (L), or oscillating disturbed flow (D). GLUT1: glucose transporter 1, GLUT3: glucose transporter 3, HK1: hexokinase 1, HK2: hexokinase 2, GPI: glucose-6-phosphate isomerase, PFK-1: phosphofructokinase-1, PFKFB3: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, ALDO-A: aldolase A, ALDO-C: aldolase C, TPI-1: Triosephosphate isomerase-1, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, PGK-1: phosphoglycerate kinase-1, PGK-2: phosphoglycerate kinase-2, PGM-1: phosphoglucomutase-1, PGM-5: phosphoglucomutase-5, <t>ENO-1:</t> <t>enolase-1,</t> ENO-3: enolase-3, LDH-A: lactate dehydrogenase A, LDH-B: lactate dehydrogenase B, PKM-1: pyruvate kinase-1, PFKM-2: pyruvate kinase-2. n = 3 samples per condition.
    Antibodies Eno1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies eno1/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    antibodies eno1 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Santa Cruz Biotechnology α eno1
    Glycolytic enzyme expression and protein levels did not change in HUVECs exposed to steady laminar versus oscillating disturbed flow. Relative ( A ) mRNA levels measured via RT-PCR, and ( B ) protein levels measured via Western blot of glycolytic enzymes in HUVEC exposed to static culture (S), steady laminar flow (L), or oscillating disturbed flow (D). GLUT1: glucose transporter 1, GLUT3: glucose transporter 3, HK1: hexokinase 1, HK2: hexokinase 2, GPI: glucose-6-phosphate isomerase, PFK-1: phosphofructokinase-1, PFKFB3: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, ALDO-A: aldolase A, ALDO-C: aldolase C, TPI-1: Triosephosphate isomerase-1, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, PGK-1: phosphoglycerate kinase-1, PGK-2: phosphoglycerate kinase-2, PGM-1: phosphoglucomutase-1, PGM-5: phosphoglucomutase-5, <t>ENO-1:</t> <t>enolase-1,</t> ENO-3: enolase-3, LDH-A: lactate dehydrogenase A, LDH-B: lactate dehydrogenase B, PKM-1: pyruvate kinase-1, PFKM-2: pyruvate kinase-2. n = 3 samples per condition.
    α Eno1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/α eno1/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    α eno1 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Santa Cruz Biotechnology anti enolase 1
    Glycolytic enzyme expression and protein levels did not change in HUVECs exposed to steady laminar versus oscillating disturbed flow. Relative ( A ) mRNA levels measured via RT-PCR, and ( B ) protein levels measured via Western blot of glycolytic enzymes in HUVEC exposed to static culture (S), steady laminar flow (L), or oscillating disturbed flow (D). GLUT1: glucose transporter 1, GLUT3: glucose transporter 3, HK1: hexokinase 1, HK2: hexokinase 2, GPI: glucose-6-phosphate isomerase, PFK-1: phosphofructokinase-1, PFKFB3: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, ALDO-A: aldolase A, ALDO-C: aldolase C, TPI-1: Triosephosphate isomerase-1, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, PGK-1: phosphoglycerate kinase-1, PGK-2: phosphoglycerate kinase-2, PGM-1: phosphoglucomutase-1, PGM-5: phosphoglucomutase-5, <t>ENO-1:</t> <t>enolase-1,</t> ENO-3: enolase-3, LDH-A: lactate dehydrogenase A, LDH-B: lactate dehydrogenase B, PKM-1: pyruvate kinase-1, PFKM-2: pyruvate kinase-2. n = 3 samples per condition.
    Anti Enolase 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti enolase 1/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti enolase 1 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    Image Search Results


    Forest plot illustrating the association of ENO1 expression with AML patient overall survival. The hazard ratios (HR) of individual studies are shown as squares sized to reflect the indicated weight of each study in the overall estimate; 95% confidence intervals (CI) are shown as horizontal lines. The pooled HR from all studies combined (total, random effects) is shown as a diamond. The calculated p -value and heterogeneity estimate (I 2 ) are indicated.

    Journal: Cancers

    Article Title: High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia

    doi: 10.3390/cancers16050884

    Figure Lengend Snippet: Forest plot illustrating the association of ENO1 expression with AML patient overall survival. The hazard ratios (HR) of individual studies are shown as squares sized to reflect the indicated weight of each study in the overall estimate; 95% confidence intervals (CI) are shown as horizontal lines. The pooled HR from all studies combined (total, random effects) is shown as a diamond. The calculated p -value and heterogeneity estimate (I 2 ) are indicated.

    Article Snippet: Briefly, 4 μm sections of formalin-fixed paraffin-embedded tissues were cut onto glass slides and dried at 45 °C for minimum 2 h. Slides were loaded on to the instrument for heat fixing and dewaxing, before blocking and application of anti-ENO1 antibody (1/12,000; Santa Cruz sc10082) for 32 min at 36 °C degrees.

    Techniques: Expressing

    ENO1 protein expression in bone marrow trephine biopsies from AML at diagnosis and remission compared to MDS at diagnosis. Representative low power (20×) micrographs of immunohistochemical staining for ENO1 in ( A ) AML at diagnosis, ( B ) AML at remission, and ( C ) MDS at diagnosis, where presence of ENO1 is indicated by brown staining. QuPath analysis results for the percentage of positive cells ( D ) and H-score staining intensity ( E ) in each cohort. Comparison of blast cell percentages from bone marrow aspirates is illustrated in ( F ), and lack of correlation with ENO1 percentage of positive cell staining in ( G ) and H-score in ( H ). Bar graphs illustrate median/interquartile range. Ns = not significant.

    Journal: Cancers

    Article Title: High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia

    doi: 10.3390/cancers16050884

    Figure Lengend Snippet: ENO1 protein expression in bone marrow trephine biopsies from AML at diagnosis and remission compared to MDS at diagnosis. Representative low power (20×) micrographs of immunohistochemical staining for ENO1 in ( A ) AML at diagnosis, ( B ) AML at remission, and ( C ) MDS at diagnosis, where presence of ENO1 is indicated by brown staining. QuPath analysis results for the percentage of positive cells ( D ) and H-score staining intensity ( E ) in each cohort. Comparison of blast cell percentages from bone marrow aspirates is illustrated in ( F ), and lack of correlation with ENO1 percentage of positive cell staining in ( G ) and H-score in ( H ). Bar graphs illustrate median/interquartile range. Ns = not significant.

    Article Snippet: Briefly, 4 μm sections of formalin-fixed paraffin-embedded tissues were cut onto glass slides and dried at 45 °C for minimum 2 h. Slides were loaded on to the instrument for heat fixing and dewaxing, before blocking and application of anti-ENO1 antibody (1/12,000; Santa Cruz sc10082) for 32 min at 36 °C degrees.

    Techniques: Expressing, Immunohistochemical staining, Staining, Comparison

     Anti-ENO1 antibody  levels in AML, MDS, and control cohorts.

    Journal: Cancers

    Article Title: High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia

    doi: 10.3390/cancers16050884

    Figure Lengend Snippet: Anti-ENO1 antibody levels in AML, MDS, and control cohorts.

    Article Snippet: Briefly, 4 μm sections of formalin-fixed paraffin-embedded tissues were cut onto glass slides and dried at 45 °C for minimum 2 h. Slides were loaded on to the instrument for heat fixing and dewaxing, before blocking and application of anti-ENO1 antibody (1/12,000; Santa Cruz sc10082) for 32 min at 36 °C degrees.

    Techniques:

    Anti-ENO1 antibodies in AML and MDS patients and controls. ( A ) Box plot showing median anti-ENO1 levels measured for each cohort, with whiskers and outliers calculated using Tukey’s method. ( B ) Scatterplot of age vs. anti-ENO1 levels showing linear trend lines.

    Journal: Cancers

    Article Title: High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia

    doi: 10.3390/cancers16050884

    Figure Lengend Snippet: Anti-ENO1 antibodies in AML and MDS patients and controls. ( A ) Box plot showing median anti-ENO1 levels measured for each cohort, with whiskers and outliers calculated using Tukey’s method. ( B ) Scatterplot of age vs. anti-ENO1 levels showing linear trend lines.

    Article Snippet: Briefly, 4 μm sections of formalin-fixed paraffin-embedded tissues were cut onto glass slides and dried at 45 °C for minimum 2 h. Slides were loaded on to the instrument for heat fixing and dewaxing, before blocking and application of anti-ENO1 antibody (1/12,000; Santa Cruz sc10082) for 32 min at 36 °C degrees.

    Techniques:

    Characteristics of the MDS patient cohort.

    Journal: Cancers

    Article Title: High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia

    doi: 10.3390/cancers16050884

    Figure Lengend Snippet: Characteristics of the MDS patient cohort.

    Article Snippet: Briefly, 4 μm sections of formalin-fixed paraffin-embedded tissues were cut onto glass slides and dried at 45 °C for minimum 2 h. Slides were loaded on to the instrument for heat fixing and dewaxing, before blocking and application of anti-ENO1 antibody (1/12,000; Santa Cruz sc10082) for 32 min at 36 °C degrees.

    Techniques:

    Characteristics of the AML patient cohort.

    Journal: Cancers

    Article Title: High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia

    doi: 10.3390/cancers16050884

    Figure Lengend Snippet: Characteristics of the AML patient cohort.

    Article Snippet: Briefly, 4 μm sections of formalin-fixed paraffin-embedded tissues were cut onto glass slides and dried at 45 °C for minimum 2 h. Slides were loaded on to the instrument for heat fixing and dewaxing, before blocking and application of anti-ENO1 antibody (1/12,000; Santa Cruz sc10082) for 32 min at 36 °C degrees.

    Techniques: Mutagenesis

    Anti-ENO1 antibodies in AML patients. ( A ) Scatterplot of BM blast percentage vs. anti-ENO1 levels showing linear trend line (solid red line) and 95% confident intervals (dotted red lines). ( B ) Comparison of Kaplan–Meier curves for AML patients with anti-ENO1 levels above and below the calculated median of 1.39 ng/mL.

    Journal: Cancers

    Article Title: High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia

    doi: 10.3390/cancers16050884

    Figure Lengend Snippet: Anti-ENO1 antibodies in AML patients. ( A ) Scatterplot of BM blast percentage vs. anti-ENO1 levels showing linear trend line (solid red line) and 95% confident intervals (dotted red lines). ( B ) Comparison of Kaplan–Meier curves for AML patients with anti-ENO1 levels above and below the calculated median of 1.39 ng/mL.

    Article Snippet: Briefly, 4 μm sections of formalin-fixed paraffin-embedded tissues were cut onto glass slides and dried at 45 °C for minimum 2 h. Slides were loaded on to the instrument for heat fixing and dewaxing, before blocking and application of anti-ENO1 antibody (1/12,000; Santa Cruz sc10082) for 32 min at 36 °C degrees.

    Techniques: Comparison

    Glycolytic enzyme expression and protein levels did not change in HUVECs exposed to steady laminar versus oscillating disturbed flow. Relative ( A ) mRNA levels measured via RT-PCR, and ( B ) protein levels measured via Western blot of glycolytic enzymes in HUVEC exposed to static culture (S), steady laminar flow (L), or oscillating disturbed flow (D). GLUT1: glucose transporter 1, GLUT3: glucose transporter 3, HK1: hexokinase 1, HK2: hexokinase 2, GPI: glucose-6-phosphate isomerase, PFK-1: phosphofructokinase-1, PFKFB3: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, ALDO-A: aldolase A, ALDO-C: aldolase C, TPI-1: Triosephosphate isomerase-1, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, PGK-1: phosphoglycerate kinase-1, PGK-2: phosphoglycerate kinase-2, PGM-1: phosphoglucomutase-1, PGM-5: phosphoglucomutase-5, ENO-1: enolase-1, ENO-3: enolase-3, LDH-A: lactate dehydrogenase A, LDH-B: lactate dehydrogenase B, PKM-1: pyruvate kinase-1, PFKM-2: pyruvate kinase-2. n = 3 samples per condition.

    Journal: International Journal of Molecular Sciences

    Article Title: Steady Laminar Flow Decreases Endothelial Glycolytic Flux While Enhancing Proteoglycan Synthesis and Antioxidant Pathways

    doi: 10.3390/ijms25052485

    Figure Lengend Snippet: Glycolytic enzyme expression and protein levels did not change in HUVECs exposed to steady laminar versus oscillating disturbed flow. Relative ( A ) mRNA levels measured via RT-PCR, and ( B ) protein levels measured via Western blot of glycolytic enzymes in HUVEC exposed to static culture (S), steady laminar flow (L), or oscillating disturbed flow (D). GLUT1: glucose transporter 1, GLUT3: glucose transporter 3, HK1: hexokinase 1, HK2: hexokinase 2, GPI: glucose-6-phosphate isomerase, PFK-1: phosphofructokinase-1, PFKFB3: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, ALDO-A: aldolase A, ALDO-C: aldolase C, TPI-1: Triosephosphate isomerase-1, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, PGK-1: phosphoglycerate kinase-1, PGK-2: phosphoglycerate kinase-2, PGM-1: phosphoglucomutase-1, PGM-5: phosphoglucomutase-5, ENO-1: enolase-1, ENO-3: enolase-3, LDH-A: lactate dehydrogenase A, LDH-B: lactate dehydrogenase B, PKM-1: pyruvate kinase-1, PFKM-2: pyruvate kinase-2. n = 3 samples per condition.

    Article Snippet: After blocking in 5% BSA, membranes were incubated with primary antibodies for hexokinase 1 (46695), hexokinase 2 (374091), phosphofructokinase-1 (166722), aldolase A (390733), phosphoglycerate kinase (48342), phosphoglucomutase-1 (373796), lactate dehydrogenase (133123), glucose-6-phosphate dehydrogenase (373886), and enolase-1 (100812, all from Santa Cruz), as well as PFKFB3 (13123S) and GFAT1 (5322, from Cell Signaling, Danvers, MA, USA) at a 1:1000 dilution overnight at 4 °C followed by the appropriate secondary horseradish peroxidase-conjugated antibody (1:2000; Promega, Madison, WI, USA) for 1 h at room temperature. β-actin (SC47778-C4, Santa Cruz, Dallas, TX, USA) was used as the loading control.

    Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot

    PCR primer sequences.

    Journal: International Journal of Molecular Sciences

    Article Title: Steady Laminar Flow Decreases Endothelial Glycolytic Flux While Enhancing Proteoglycan Synthesis and Antioxidant Pathways

    doi: 10.3390/ijms25052485

    Figure Lengend Snippet: PCR primer sequences.

    Article Snippet: After blocking in 5% BSA, membranes were incubated with primary antibodies for hexokinase 1 (46695), hexokinase 2 (374091), phosphofructokinase-1 (166722), aldolase A (390733), phosphoglycerate kinase (48342), phosphoglucomutase-1 (373796), lactate dehydrogenase (133123), glucose-6-phosphate dehydrogenase (373886), and enolase-1 (100812, all from Santa Cruz), as well as PFKFB3 (13123S) and GFAT1 (5322, from Cell Signaling, Danvers, MA, USA) at a 1:1000 dilution overnight at 4 °C followed by the appropriate secondary horseradish peroxidase-conjugated antibody (1:2000; Promega, Madison, WI, USA) for 1 h at room temperature. β-actin (SC47778-C4, Santa Cruz, Dallas, TX, USA) was used as the loading control.

    Techniques: Sequencing